weight gain or nausea.
* Isis initiated Phase 1 studies of ISIS 325568, an antisense drug
partnered with OMI, that targets the glucagon receptor, GCGR.
* Isis identified a development candidate, ISIS 377131, an antisense
drug also partnered with OMI that
targets the glucocorticoid receptor, GCCR.
* Isis added ISIS 388626 to its development pipeline. ISIS 388626
targets SGLT2, a protein that is responsible for glucose re-absorption
in the kidney. Cancer continues to be a disease in which antisense drugs could make a
profound difference in treatment options. Isis' partners are developing
antisense drugs discovered by Isis to treat cancer.
* OncoGenex reported encouraging Phase 2 data for OGX-011, an antisense
drug that targets clusterin, in several studies in patients with
advanced prostate or lung cancers. The most recent study showed that
OGX-011 was well-tolerated in combination with certain chemotherapy
agents and showed ongoing survival durations that were more favorable
than with the chemotherapy agents alone, based on historical controls.
* OncoGenex initiated Phase 1 clinical studies of OGX-427, an antisense
drug that targets Hsp27, a cell survival protein that is overly
abundant in cancer cells.
* Lilly advanced its Phase 1 studies of LY2275796, which targets eIF-4E,
a protein involved in tumor progression and in the Journal of Clinical
Investigation, Isis and Lilly published preclinical study results that
support the therapeutic potential of LY2275796. Isis is exploring new applications and disease indications for
antisense drugs to treat neurodegenerative diseases and other diseases for
which antisense drugs are uniquely suited.
* Isis was granted orphan drug status
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved